Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study

Dupilumab, targeting the interleukin-4 α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited dat...

Source: BMC Dermatology - September 22, 2020 Category: Dermatology Authors: Emma Kristin Johansson, Lina Ulrika Ivert, Baltzar Bradley, Maria Lundqvist and Maria Bradley Tags: Research article Source Type: research